Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Forte Biosciences, Inc. (FBRX) Liabilities and Shareholders Equity (2016 - 2020)

Forte Biosciences (FBRX) has disclosed Liabilities and Shareholders Equity for 5 consecutive years, with $22.7 million as the latest value for Q3 2020.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 67.87% to $22.7 million in Q3 2020 year-over-year; TTM through Dec 2020 was $69.7 million, a 73.03% decrease, with the full-year FY2019 number at $7.7 million, down 92.57% from a year prior.
  • Liabilities and Shareholders Equity was $22.7 million for Q3 2020 at Forte Biosciences, down from $28.3 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $110.8 million in Q2 2017 to a low of $7.7 million in Q4 2019.
  • A 5-year average of $66.4 million and a median of $82.0 million in 2018 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 160.45% in 2017, then tumbled 92.57% in 2019.
  • Forte Biosciences' Liabilities and Shareholders Equity stood at $35.4 million in 2016, then surged by 160.45% to $92.1 million in 2017, then rose by 11.96% to $103.1 million in 2018, then crashed by 92.57% to $7.7 million in 2019, then skyrocketed by 196.81% to $22.7 million in 2020.
  • Per Business Quant, the three most recent readings for FBRX's Liabilities and Shareholders Equity are $22.7 million (Q3 2020), $28.3 million (Q2 2020), and $18.6 million (Q1 2020).